Pharma Times -- Novartis has bagged another approval for its multiple sclerosis pill, Gilenya, this time in Canada. Health Canada has given the green light to Gilenya (fingolimod), making it the first disease-modifying oral therapy developed for the relapsing-remitting form of MS to get approval in the country.
